海尔生物实控人方拟套现0.9亿元 2019年上市募12.31亿元

Core Viewpoint - Haier Biomedical (688139.SH) announced a share reduction plan by its shareholder, Qingdao Haichuangrui Equity Investment Fund Center, due to funding needs, intending to reduce up to 0.85% of its total shares, equating to a maximum of 2,690,189 shares [1] Group 1 - Haichuangrui plans to reduce its holdings in Haier Biomedical through centralized bidding, with a reduction period starting 15 trading days after the announcement and lasting for three months [1] - As of the last trading day before the announcement, Haier Biomedical's share price was 33.34 yuan per share, estimating the reduction amount to be approximately 89.69 million yuan [1] - Haichuangrui currently holds 32,103,659 shares of Haier Biomedical, representing 10.14% of the total share capital [1] Group 2 - Haichuangrui has signed a voting rights entrustment agreement with Haier Group, establishing a concerted action relationship [2] - Haier Group, through its controlled entity, Qingdao Haier Biomedical Medical Holdings, holds 100,591,463 shares, accounting for 31.78% of Haier Biomedical's total shares [2] - Another concerted action partner, Qingdao Haichuangzhi Management Consulting Enterprise, holds 8,675,900 shares, representing 2.74% of the total shares [2] Group 3 - Haier Biomedical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 25, 2019, after receiving approval from the Shanghai Stock Exchange and the China Securities Regulatory Commission [3] - The company issued a total of 79,267,940 shares at a price of 15.53 yuan per share, raising approximately 1.23 billion yuan, with actual funds received amounting to about 1.16 billion yuan [3] - The funds were verified by Ernst & Young Hua Ming and were received on October 22, 2019, with Guotai Junan Securities serving as the lead underwriter [3]